文献速递银屑病与炎症性皮肤病

肿瘤坏死因子抑制剂抗炎治疗与银屑病患者主要不良心血管事件风险降低相关

Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-05-01

这项回顾性队列研究基于KPSC健康计划数据,纳入至少三次银屑病ICD-9编码且无既往MACE编码的患者,采用倾向评分校正的多变量Cox回归评估TNFi使用与MACE的风险比。结果显示,校正心血管危险因素后,TNFi队列MACE风险显著低于外用治疗队列(HR 0.80,95%CI 0.66-0.98),口服/光疗队列与外用队列相似(HR 1.19,95%CI 0.99-1.42)。作者认为TNFi治疗可能对银屑病患者心血管事件风险有皮肤外获益。

要点

  • TNFi队列MACE风险显著低于外用队列(HR 0.80,95%CI 0.66-0.98)。
  • 口服/光疗队列与外用队列MACE风险相似(HR 1.19,95%CI 0.99-1.42)。
  • TNFi治疗可能具有减轻心血管事件风险的皮肤外获益。

核心结论

  • 接受TNFi治疗的银屑病患者MACE风险显著低于外用或口服/光疗药物者。
  • TNFi治疗可能具有减轻心血管事件风险的皮肤外获益。

研究设计与样本

  • 回顾性队列研究,使用KPSC健康计划数据,纳入至少三次银屑病ICD-9编码且无既往MACE编码的患者。
  • 采用倾向评分校正的多变量Cox回归评估TNFi使用与MACE的风险比。

主要发现

  • 校正心血管危险因素后,TNFi队列MACE风险显著低于外用队列(HR 0.80,95%CI 0.66-0.98)。
  • 口服/光疗队列与外用队列MACE风险相似(HR 1.19,95%CI 0.99-1.42)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis is a systemic chronic inflammatory condition associated with increased risk of cardiovascular disease. Data demonstrating that decreased skin inflammation reduces cardiovascular events in patients with psoriasis may be generalizable to other chronic inflammatory states with heightened cardiovascular risk. OBJECTIVE: To determine whether tumour necrosis factor inhibitor (TNFi) therapy is associated with decreased major adverse cardiovascular events (MACE) in patients with psoriasis. METHODS: In this retrospective cohort study using the KPSC health plan, patients had at least three ICD-9 codes for psoriasis and no antecedent MACE codes. Propensity score-adjusted multivariable Cox regression assessed hazard ratios (HR) of MACE associated with TNFi use. RESULTS: After adjusting for cardiovascular risk factors, the TNFi cohort had significantly lower MACE HR compared with the topical cohort (HR, 0.80; 95% CI, 0.66-0.98). The oral/phototherapy cohort had similar MACE HR compared with the topical cohort (HR, 1.19 (95% CI, 0.99-1.42)). CONCLUSIONS: We observed significantly lower MACE risk in patients with psoriasis receiving TNFi compared to topical or oral/phototherapy agents. TNFi therapy may have benefits beyond skin disease in mitigating cardiovascular event risk.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Wu JJ, Joshi AA, Reddy SP, et al. Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis. J Eur Acad Dermatol Venereol. 2018. PMID: 29573294. doi:10.1111/jdv.14951

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。